DMPK Insights
DMPK Insights is a bi-monthly podcast by Pharmaron that explores the latest research and developments in DMPK (drug metabolism and pharmacokinetics) science. The show focuses on three main areas: current considerations in breaking DMPK science, including recent publications and regulatory updates; influential individuals in the field, highlighting their career paths and research; and trending technologies in DMPK science, explaining what they do and why they are needed.
Episodes
DMPK Insights #16: HR-LC/MS: A Key Consideration for Environmental Fate and Plant/Livestock Metabolism Studies
For a captioned and video version or to access the transcript and ask a question for our experts about this podcast episode, please visit: https://www.pharmaron.com/knowledge-center/dmpk-insights-16-metabolism-studies/#cprtstatus=_cp_0!channel!AAIDoxPJjQQeIn this special episode of the Pharmaron DMPK Insights Podcast Series, our experts explore the critical role of metabolism studies in agrochemic
DMPK Insights #15: Pharmacokinetics-Pharmacodynamics: Driving decision making with PKPD throughout Drug Discovery
For a captioned version or to access the transcript and ask a question for our experts about this podcast episode, please visit: https://www.pharmaron.com/knowledge-center/dmpk-insights-15-pkpd-drug-discovery/In this episode of the Pharmaron DMPK Insights Podcast Series, Simon Taylor and Dr. Emile Chen discuss the relationship of drug concentration and effect (PKPD). PKPD is critical to decision
DMPK Insights #14: Evolution of CNS Drug Disposition Models
For a captioned version or to access the transcript, please visit: https://www.pharmaron.com/knowledge-center/dmpk-insights-14-cns-modelling/In this podcast, Scott Summerfield and Professor Elizabeth de Lange discuss the evolution of CNS drug disposition models, highlighting the increasing sophistication of physiologically based pharmacokinetic (PBPK) models, such as LeiCNS-PK3.0. They discuss how
DMPK Insights #13: The Influence of QSAR and Physicochemical Descriptors on Drug Design: A Brief History and New Paradigms
For a captioned version or to access the transcript, please visit: https://www.pharmaron.com/knowledge-center/dmpk-insights-13-qsar-physicochemical-descriptors/In this podcast, Scott Summerfield and Matt Segall will discuss QSAR and how in silico ADME science has evolved to influence Drug Design and improve the ADME properties of hit and lead compounds.We will address the following questions: Wha
DMPK Insights #12: New Frontiers in Understanding the BBB Transport of Small Molecule Drugs
For a captioned version or to access the transcript, please visit: https://www.pharmaron.com/knowledge-center/dmpk-insights-12-bbb-transporters/In this podcast, Elena and Mikko will discuss the current state-of-the-art around transporter sub-types and their expression within the blood-brain barrier (BBB) and opportunities for utilizing these transporters for brain drug delivery. We will address th
DMPK Insights #11: Drug Meets Bug: How the Gut Microbiome Shapes DMPK
For a captioned version or to access the transcript, please visit https://www.pharmaron.com/knowledge-center/dmpk-podcast-11-gut-microbiome/.In this podcast, Chris Bode (Pharmaron US Labs) interviews Peter Turnbaugh, a microbiologist and Professor of Microbiology and Immunology at the University of California San Francisco. Over the past 15-20 years, Peter has produced so much groundbreaking resea
DMPK Insights #10: The DMPK Project Representative: An essential role of contribution, integration and evolution
In this podcast Simon Taylor (Pharmaron UK) interviews Kevin Beaumont, a highly experienced DMPK scientist, leader and drug developer who has lived and breathed the role of the DMPK Project Representative throughout his 40-year industrial career. With experience of delivering clinical drug candidates across multiple therapeutic areas with two major pharma companies (Pfizer and AstraZeneca) Kevin
DMPK Insights #9: 60 and Beyond: Navigating the Frontiers of PBPK and QSP
In this podcast, listeners will join us in celebrating the remarkable career of Professor Amin Rostami, a trailblazer in the realms of PBPK and QSP. Following his 60th birthday, Professor Rostami will provide insights into his journey, the dynamic evolution of PBPK and QSP, and the exciting horizons ahead. Tune in for a deep dive into the intersections of academia and industry, technological advan
DMPK Insights #8: It’s “All-go” with Oligos: Challenges and Opportunities in LC-MS of Therapeutic
In this podcast, Robert MacNeill, Professor Michael Bartlett of the University of Georgia and Dr. Guilherme Guimaraes of Biogen, will focus on oligonucleotide LC-MS covering the exciting key challenges, the pivotal nature of sensitivity in such assays, and the various analytical approaches and technologies that have been used, currently in use or being developed. The episode explores the following
DMPK Insights #7: Carboxylic Acids and DILI – Conjugation and Reputation
In this podcast, Professor Ian Wilson, a globally recognised and leading expert in drug metabolism, with over 500 publications in the field, takes us on an engaging journey exploring the link between carboxylic acid containing drugs and their involvement in DILI. A special focus will be given to Ian’s latest paper: ‘Minimizing the DILI potential of carboxylic acid-containing drugs: a perspective’.
DMPK Insights #6: Protein Mass Spectrometry: Advancing the Bioanalysis of Biotherapeutics and Biomarkers
In this podcast, Scott and John will discuss the LC-MS techniques that have been applied for the bioanalysis of biotherapeutics.The episode explores the following:The impact that mass spectrometry is having in the biotherapeutics and biomarker spaceThe rationale behind the use of LC-MS for certain biomarkers and how sensitive LC-MS assays can be developed (and the practical limits for lower limits
DMPK Insights #4: DMPK Past, Present and Future – A Festive Tale
This podcast format is inspired by the Charles Dicken’s novella “A Christmas Carol” whereby Phil Jeffrey (Bicycle Therapeutics), Beth Williamson (UCB) and Daniel Price (Nimbus) discuss DMPK Past, Present and Future with Scott. Key elements discussed include the evolution of DMPK as a predictive discipline that links helps the chemistry of drug design with the biology of drug disposition and effec
DMPK Insights #5: Mass Spectrometry Imaging - Past, Present and Future
In this podcast, Josephine Bunch, Principal Research Scientist and Co-Director of the National Centre of Excellence in Mass Spectrometry (NiCE-MSI) at NPL, talks about her work, and in particular her involvement in the Cancer Research UK Grand Challenge Programme. The episode explores the following:Recent innovations in MSI Challenges associated with analyzing ever more complex moleculesLabel-fr
DMPK Insights #3: Free Drug Theory: No Longer Just a Hypothesis?
In this podcast, Scott Summerfield, Senior Director, Pharmaceutical Metabolism at Pharmaron discusses his recent publication on Free Drug Theory (FDT) with Simon including the principles, arguments, and project impact. This article was an invited contribution to a special edition of the Pharmaceutical Research Journal recognizing the achievements of Professor Margareta Hammarlund-Udenaes and Kp,uu
DMPK Insights #2: Pathways to Successful Drug Design – Discovery Metabolite ID
In this podcast, Dan Weston, Scientific Leader, Biotransformation at GSK discusses his recent publication on the important role that Metabolite ID plays in drug discovery.The episode addresses the following questions:Why studying biotransformation is an important part of early drug design A strategy to combine in silico tools, high-resolution MS and software-assisted data analysis to optimize data
DMPK Insights #1: Candidate Survival – 3 Pillars to 5Rs and Beyond
In this podcast, Dr. Paul Morgan, Head of DMPK at Grünenthal Group, discusses the development of the publication that introduced the “5R framework” and improved the likelihood of AstraZeneca candidate survival from candidate drug nomination to Phase III. We will then discuss how the area has developed since then and where the field may go in the future.The episode addresses the following questions
